Answers are grounded in this paper and cite their sources.
Chimeric antigen receptor (CAR) T-cell therapy has emerged as a potential treatment for patients with B-cell lymphoma in whom standard therapy has failed. The U.S. Food and Drug Administration (FDA) has approved anti-CD19 CAR T-cell products for B-cell lymphoma. However, growing experience has shown that treatment has limitations, such as relapses due to tumour mutations or CD19 antigen loss, unexpanded CAR T-cells, and/or poor persistence of CAR T-cells. Understanding the limitations of CAR T-cell therapy is essential to achieve the full potential of this therapeutic strategy. In this review, we analyse factors potentially affecting the efficacy of CAR T-cell therapy, explore the mechanisms of resistance to CD19 CAR T-cell therapy in B-cell lymphoma, and summarise potential strategies to overcome treatment barriers.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: